Abilash Sathyanarayanan

Abilash Sathyanarayanan

Auto-generated profile, based on publicly available information

Abilash Sathyanarayanan

Diabetes and Endocrinology, Nottingham University Hospitals, Nottingham, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2024 in Journal of Human Hypertension
Verified
Journal Article
Open access
PDF file
LFLuca Faconti
Luca Faconti
JGJacob George
Jacob George
SPSarah Partridge
Sarah Partridge
CMCarmen Maniero
Carmen Maniero
ASAbilash Sathyanarayanan
Abilash Sathyanarayanan
IWIan B. Wilkinson
Ian B. Wilkinson
People living with resistant hypertension (RH) are at high risk of adverse cardiovascular events. The British and Irish Hypertension Society has identified suspected RH as a condition for which specialist guidance may improve rates of blood pressure control and help clinicians identify those individuals who may benefit from specialist review. In this position statement we provide a practical approach for the investigation and management of adults with RH. We highlight gaps in the current evidence and identify important future research questions. Our aim is to support the delivery of high-quality and consistent care to people living with RH across the UK and Ireland.

2 April 2024 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
ASAbilash Sathyanarayanan
Abilash Sathyanarayanan
IntroductionElectronic healthcare records (EHRs) came into use for practicing clinicians in the late 1980’s (1). Since then, the incorporation of EHRs in many healthcare systems has provided new op...

31 March 2026 in Clinical Medicine
Verified
Journal Article
Open access
EPEunice K.T. Phillips
Eunice K.T. Phillips
ASAbilash Sathyanarayanan
Abilash Sathyanarayanan
Primary aldosteronism (PA) is a common yet significantly underdiagnosed cause of secondary hypertension, estimated to affect around 9.4% of hypertensive adults. This is critical because patients with PA face markedly higher rates of adverse cardiovascular and renal outcomes, risks substantially mitigated by targeted treatment (surgery or medical therapy). Despite this, screening rates remain critically low. This article provides a practical, evidence-based approach to PA screening specifically for generalist settings, focusing on contemporary test interpretation and mitigating common pitfalls. Screening involves a simple blood test for plasma aldosterone and renin. The diagnostic hallmark is renin-independent aldosterone production, demonstrated by suppressed renin. While most antihypertensives interfere, the initial approach is to test patients on their current regimen. If results are inconclusive, medication withdrawal is warranted. Specialist referral is necessary when results are suggestive of PA, or in complex cases like chronic kidney disease. Improving PA screening offers a significant opportunity for substantial global benefit in reducing hypertension-related morbidity and mortality.

1 January 2018 in Journal of Clinical and Diagnostic Research
Verified
Journal Article
Open access
BKBhuvaneswari Krishnamurthy
Bhuvaneswari Krishnamurthy
PKPrashanth Ashok Kumar
Prashanth Ashok Kumar
ASAbilash Sathyanarayanan
Abilash Sathyanarayanan

10 July 2024 in Journal of Human Hypertension
Verified
Journal Article
Closed access
PDF file
ASAbilash Sathyanarayanan
Abilash Sathyanarayanan